AZN · story · 27 October – 28 October
AstraZeneca · 4 headlines from 4 outlets, from 27 October 2026 to 28 October 2026.
Results from the PACIFIC-9 study in lung cancer are now expected in the first half of 2027.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
TipRanks is the largest at −3.3, ahead of grafa.com (−4.2). Investing.com Canada is the lowest at −6.3.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Investing.com Canada | −6.3 |
| Quantisnow | −5.8 |
| grafa.com | −4.2 |
| TipRanks | −3.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Investing.com Canada | 1 | −6.3 |
| Quantisnow | 1 | −5.8 |
| grafa.com | 1 | −4.2 |
| TipRanks | 1 | −3.3 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| −4.2 | Trial data pushed back to 2027, delaying a pipeline readout. |
| −3.3 | Revised later timing for a trial readout. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| −6.3 | Data timing for lung cancer study slips by a long stretch. |
| −5.8 | Trial readout pushed back to 2027, a setback for AZN's lung programme. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.